목적: 안구건조증 환자에서 레스타시스® (Cyclosporine 0.05%, Allergan Inc., U.S.A.)를 사용하고 눈물 분비량의 변화와 안구건조증 증상을 알아보았다. 대상과 방법: 안구건조증을 진단받은 39명을 대상으로 3개월간 레스타시스®를 점안하고 1개월마다 1형 및 2형 쉬르머검사와 눈물막파괴시간을 측정하였고, 안구건조증의 증상을 따가움, 가려움, 이물감, 시야흐림, 광과민증으로 나누어 0~5점까지 점수화하여 분석하였다. 결과: 대상자 39명 중 26명(52안)의 1형 및 2형 쉬르머검사와 눈물막파괴시간이 치료 전 10±7.23 mm, 7.0±4.88 mm, 6.30±2.31초이었던 것이 3개월 후 12.67±7.11 mm, 9.48±5.30 mm, 7.29±1.95초로 모두 의미있게 증가하였다(P는 각각 0.012, 0.009, 0.001). 안구건조증의 증상은 이물감만이 유의하게 개선된 것으로 나타났다(P는 0.010). 결론: 3개월간의 레스타시스® 사용 후 눈물분비량이 증가하고, 특히 전신질환과 동반된 안구건조증에서 더 큰 효과가 나타났다.
목적: 안구건조증 환자에서 레스타시스® (Cyclosporine 0.05%, Allergan Inc., U.S.A.)를 사용하고 눈물 분비량의 변화와 안구건조증 증상을 알아보았다. 대상과 방법: 안구건조증을 진단받은 39명을 대상으로 3개월간 레스타시스®를 점안하고 1개월마다 1형 및 2형 쉬르머검사와 눈물막파괴시간을 측정하였고, 안구건조증의 증상을 따가움, 가려움, 이물감, 시야흐림, 광과민증으로 나누어 0~5점까지 점수화하여 분석하였다. 결과: 대상자 39명 중 26명(52안)의 1형 및 2형 쉬르머검사와 눈물막파괴시간이 치료 전 10±7.23 mm, 7.0±4.88 mm, 6.30±2.31초이었던 것이 3개월 후 12.67±7.11 mm, 9.48±5.30 mm, 7.29±1.95초로 모두 의미있게 증가하였다(P는 각각 0.012, 0.009, 0.001). 안구건조증의 증상은 이물감만이 유의하게 개선된 것으로 나타났다(P는 0.010). 결론: 3개월간의 레스타시스® 사용 후 눈물분비량이 증가하고, 특히 전신질환과 동반된 안구건조증에서 더 큰 효과가 나타났다.
Purpose: We conducted a study to evaluate the change of tear secretion and symptoms in the patients with dry eye syndrome after using Restasis® (Cyclosporine 0.05% ophthalmic emulsion, Allergan Inc., U.S.A.). Methods: We randomly selected 39 patients from newly or previously diagnosed dry eye syndro...
Purpose: We conducted a study to evaluate the change of tear secretion and symptoms in the patients with dry eye syndrome after using Restasis® (Cyclosporine 0.05% ophthalmic emulsion, Allergan Inc., U.S.A.). Methods: We randomly selected 39 patients from newly or previously diagnosed dry eye syndrome patients and administered Restasis® to them. We checked their clinical parameters and symptoms over a period of 3 months. The clinical parameters evaluated were type I and type II Schirmer tests and tear break-up time, and the symptoms of dry eye syndrome were classified into pain, itching, foreign body sensation, blurred vision, and photophobia using a scoring scale for symptoms of 0 to 5. The results were analyzed with a Mann-Whitney test (P-values <0.05 was considered statistically significant). Results: For 26 of 39 patients (52 eyes) on whom all tests were carried out for 3 months, there was a significant improvement after 3 months in the type I Schirmer test, type II Schirmer test, and tear break-up time (P=0.012, 0.009, 0.001, respectively). Only 14 patients completed the questionnaire for scoring of symptoms. After using Restasis®, foreign body sensation only improved (P=0.010). Conclusions: In our study, tear secretion was increased by Restasis®, and a greater increase in tear secretion was seen in patients with systemic disease than in patients without systemic disease. Additional patients need to be evaluated and longer-term studies need to be performed to confirm our results.
Purpose: We conducted a study to evaluate the change of tear secretion and symptoms in the patients with dry eye syndrome after using Restasis® (Cyclosporine 0.05% ophthalmic emulsion, Allergan Inc., U.S.A.). Methods: We randomly selected 39 patients from newly or previously diagnosed dry eye syndrome patients and administered Restasis® to them. We checked their clinical parameters and symptoms over a period of 3 months. The clinical parameters evaluated were type I and type II Schirmer tests and tear break-up time, and the symptoms of dry eye syndrome were classified into pain, itching, foreign body sensation, blurred vision, and photophobia using a scoring scale for symptoms of 0 to 5. The results were analyzed with a Mann-Whitney test (P-values <0.05 was considered statistically significant). Results: For 26 of 39 patients (52 eyes) on whom all tests were carried out for 3 months, there was a significant improvement after 3 months in the type I Schirmer test, type II Schirmer test, and tear break-up time (P=0.012, 0.009, 0.001, respectively). Only 14 patients completed the questionnaire for scoring of symptoms. After using Restasis®, foreign body sensation only improved (P=0.010). Conclusions: In our study, tear secretion was increased by Restasis®, and a greater increase in tear secretion was seen in patients with systemic disease than in patients without systemic disease. Additional patients need to be evaluated and longer-term studies need to be performed to confirm our results.
AI-Helper
※ AI-Helper는 부적절한 답변을 할 수 있습니다.